DS
KYTX icon

David Shaw’s Kyverna Therapeutics KYTX Stock Holding History

David Shaw’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.18M Sell
469,346
-252,235
-35% -$2.24M ﹤0.01% 2556
2026
Q1 		$6.23M Buy
721,581
+203,069
+39% +$1.69M ﹤0.01% 2015
2025
Q4 		$4.87M Buy
+518,512
New +$3.85M ﹤0.01% 2318

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

David Shaw's KYTX Position: Q2 2026 in Review

David Shaw reduced its Kyverna Therapeutics (KYTX) stake by 35% in Q2 2026, selling an estimated $2.24M and leaving 469,346 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2556.

David Shaw first reported a position in KYTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.23M in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • David Shaw held 469,346 shares of Kyverna Therapeutics worth $4.18M as of Q2 2026.
  • David Shaw sold 252,235 Kyverna Therapeutics shares in Q2 2026, an estimated $2.24M.
  • Kyverna Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2556 holding.
  • David Shaw first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • David Shaw's Kyverna Therapeutics position peaked at $6.23M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.